<DOC>
	<DOCNO>NCT00464087</DOCNO>
	<brief_summary>The primary objective clinical trial evaluate safety switch fondaparinux either unfractionated heparin bivalirudin patient experience acute coronary syndrome undergo percutaneous coronary angioplasty .</brief_summary>
	<brief_title>Switching From Fondaparinux Bivalirudin Unfractionated Heparin ACS Patients Undergoing PCI</brief_title>
	<detailed_description>This prospective open label , randomize , multi-center registry . One hundred patient receive fondaparinux within 24 hour prior presentation coronary catheterization lab suitable percutaneous coronary intervention . The patient randomize 1:1 fashion either unfractionated heparin bivalirudin angioplasty . All patient follow throughout duration hospital stay .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<criteria>1 . The patient , male female , &gt; 18 year age ; 2 . The patient present coronary syndrome , unstable angina non ST segment elevate myocardial infarction ( NSTEMI ) define least one follow criterion : Elevated creatine kinase MB Troponin I T ( ULN ) ECG change indicative ischemia 3 . The patient schedule angiography , possible angioplasty , evaluation coronary disease ; 4 . The patient able willing conform requirement study voluntarily sign Informed Consent . 1 . ST elevate myocardial infarction within precede 48 hour ; 2 . Patient weigh 400 lb ( 181.2 kg ) less 110 lb ( 50 kg ) ; 3 . Patients present received bivalirudin , GP IIb/IIIa inhibitor lowmolecular weight heparin within precede 24 hour ; 4 . Patients receive unfractionated heparin less equal 90 minute prior fondaparinux administration . 5 . Patients known condition bleed diathesis actively bleed within previous 6 month ( GI bleed etc . ) ; 6 . Known diagnosis acute bacterial endocarditis ; 7 . Patients cardiogenic shock require intraaortic balloon pump ( IABP ) 8 . If patient warfarin ( Coumadin ) therapy ; 9 . Patients major minor stroke ( CVA TIA ) major surgery within past 6 month ; 10 . Known impaired renal function ( creatinine ≥ 3.0 mg/dL ( 265.2 μmol/L ) , ) status post renal transplant , patient chronic dialysis creatinine clearance ≤ 30 ml/min ; 11 . A platelet count le 100,000 cells/mm3 ; 12 . Known allergy fondaparinux , aspirin , clopidogrel bisulfate ( PlavixR ) , ticlopidine ( TiclidR ) , heparin , bivalirudin , contrast medically manage ; 13 . Prior angioplasty within previous 30 day ; 14 . Contraindication lowmolecular weight heparin , unfractionated heparin bivalirudin ; 15 . Pregnant lactating woman ; 16 . Any significant medical condition , investigator 's opinion , may interfere patient 's optimal participation study ; 17 . Currently participate investigational drug another device study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>